探讨新辅助化疗对结肠癌患者手术及预后的影响  

Explore New Adjuvant Chemotherapy for Patients with Colon Cancer Surgery and Prognosis

作　　者：徐建国[1] 曹洪涛[1] 王政[1] 

机构地区：[1]青海省人民医院肿瘤外科,青海西宁810007

出　　处：《中外医疗》2015年第25期34-35,共2页China & Foreign Medical Treatment

摘　　要：目的探究新辅助化疗对结肠癌患者手术以及预后的影响。方法结肠癌患者50例,随机分为试验组和对照组,每组25例,试验组采用新辅助化疗法,对照组采用常规疗法,对比两组治疗效果及预后。结果治疗前后对照组CD44v6、p27蛋白等指标对比差异无统计学意义,试验组差异有统计学意义(P<0.05),其中CD44v6蛋白指标发生显著下降,p27蛋白指标明显上升。两组预后对比,试验组治疗及恢复情况优于对照组,对照组则多出现呕吐、恶心、食欲不振、抵抗力差等情况。结论新辅助化疗对于结肠癌患者的治疗和预后有显著效果,值得在临床中推广使用。Objective To explore the new adjuvant chemotherapy in patients with colon cancer surgery and prognosis. Methods 50 patients with colon cancer, were randomly divided into trial group and control group, 25 cases in each group, experimental group using the method of neoadjuvant chemotherapy, the control group with conventional therapy. Compared two groups of therapeutic effect and prognosis. Results Before and after treatment, when test CD44v6 and p27 protein indexes of the control group, there was no statistically significant difference. But there was statistically significant difference before and after treatment of the trial group(P<0.05), of which the CD44v6 protein index dropped significantly while p27 protein index increased significantly. Treatment and prognosis of two groups, test group recovery is better than that of control group. Control group are vomiting, nausea, loss of appetite, poor resistance. Conclusion Neoadjuvant chemotherapy for the treatment and prognosis of patients with colon cancer has a significant effect. It is worth popularizing in clinical use.

关 键 词：新辅助化疗 结肠癌 临床效果 

分 类 号：R735.35[医药卫生—肿瘤]